Theriva Biologics, Inc. - Common stock (TOVX)
CUSIP: 87164U508
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common stock
- Shares outstanding
- 9,600,143
- Total 13F shares
- 1,295,504
- Share change
- +858,452
- Total reported value
- $272,379
- Price per share
- $0.21
- Number of holders
- 20
- Value change
- +$158,821
- Number of buys
- 14
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 87164U508?
CUSIP 87164U508 identifies TOVX - Theriva Biologics, Inc. - Common stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87164U508:
Top shareholders of TOVX - Theriva Biologics, Inc. - Common stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust |
13D/G
|
— |
7.7%
|
739,211
|
$300,046 | $0 | 24 Oct 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
4.9%
|
146,136
|
$206,052 | $0 | 31 Dec 2024 | |
| Empery Asset Management, LP |
13D/G
|
— |
5%
|
504,091
|
$201,636 | -$179,638 | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
1.3%
|
120,031
|
$48,625 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.64%
|
61,837
|
$25,050 | — | 30 Sep 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.38%
|
36,781
|
$15,000 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.38%
|
36,771
|
$14,896 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.37%
|
35,601
|
$14,422 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.34%
|
32,899
|
$13,327 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.29%
|
28,209
|
$11,427 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.28%
|
27,284
|
$11,053 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
22,913
|
$9,280 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.17%
|
16,382
|
$6,635 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.11%
|
10,142
|
$4,000 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.08%
|
7,506
|
$3,041 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
444
|
$172 | — | 30 Sep 2025 | |
| Clear Street Group Inc. |
13F
|
Company |
0%
|
100
|
$41 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
80
|
$32 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
59
|
$24 | — | 30 Sep 2025 | |
| IFP Advisors, Inc |
13F
|
Company |
0%
|
11
|
$4 | — | 30 Sep 2025 | |
| Wealthspire Advisors, LLC |
13F
|
Company |
0%
|
2
|
$1 | — | 30 Sep 2025 | |
| Francis Tufaro |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
100,000
|
— | — | 15 Dec 2022 |
Institutional Holders of Theriva Biologics, Inc. - Common stock (TOVX) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.